FDA approves test for molecular residual disease monitoring in patients with solid tumors: A test enables the identification of patients who are positive for ctDNA and can benefit from adjuvant atezolizumab after cystectomy.

Authors

Leah Lawrence

Published in

Cancer. Volume 132. Issue 17. Pages e70539. Sep 01, 2026.

PMID:
42676054
Bibliographic data and abstract were imported from PubMed on 01 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.